Coronavirus: Vaccines and Treatments
When Albert Bourla took over as CEO of Pfizer in January 2019, he said he wanted the pharmaceutical giant to be a more focused, innovative, science-based company. Bourla now finds himself at the forefront of developing and testing a COVID-19 vaccine in partnership with Germany's BioNTech. Underway with a late-stage clinical trial for its vaccine, if successful, Pfizer said they could supply up to 100 million doses of the vaccine by the end of 2020. Bourla discussed the timeline for a safe and effective vaccine and the state of the health industry during these uncertain times.
